Educational Webinar Series -- Five Years Since Azedra FDA Approval: What Have We Learned?

OSU’s Dr. Vineeth Sukrithan joins us for an in-depth look at Azedra, the first drug developed specifically for the treatment of pheochromocytoma and paraganglioma, and how it’s used in a clinical setting. Part of the Pheo Para Alliance Education Webinar Series. Questions and Timing: Q 1 at 41:19 Have you seen results with bony mets and this therapy? Q 2 at 42:30 Do you have data on how long/effective Azedra is at stopping bone mets from growing/spreading? Q 3 at 43:10 How does PRRT compare to Azedra? Q 4 at 45:55 Do you think in the future people could be possibly combining these medications? Q 5 at 47:16 My son had two doses in 2021 and we believe it has saved his life at this point. I am curious: Are patient data and results continually to be collected by all who use Azedra, and shared for the benefit of all patients? Q 6 at 50:04 How are very extreme labile blood pressures managed? Q 7 at 52:47 Is there any reason why I shouldn’t be prescribed Azedra? Q 8 at 55:33 I have been living with a large paraganglioma which cannot be removed for safety reasons. Would this treatment benefit me and how? Q 9 at 56:25 Does this disease tend to get worse with age? Q 10 at 57:57 Why the blood -- why does it affect the SAEs there?